Neuphoria Therapeutics (NEUP) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on therapies for neuropsychiatric disorders, notably PTSD and social anxiety disorder (SAD).

• Lead candidate BNC210 targets the α7 nicotinic acetylcholine receptor for both acute and chronic anxiety-related conditions.

• Pipeline includes next-generation α7 receptor modulators and Kv3.1/3.2 preclinical programs.

• Strategic partnership with Merck for early-stage CNS drug development, including Alzheimer's disease.

• Redomiciled from Australia to Delaware in December 2024, with Bionomics as a wholly-owned subsidiary.

Financial performance and metrics

• As of January 3, 2025, public float was approximately $10.8 million, with 1,628,659 shares outstanding.

• In the past 12 months, raised $1.48 million from the sale of 1,200,578 ADSs.

• Cash and cash equivalents as of September 30, 2024, were $8.1 million; pro forma $9.8 million after the offering.

• Net tangible book value per share as of September 30, 2024, was $1.76; would rise to $2.83 after the offering, with dilution of $0.57 per share at $3.40 per share offering price.

Use of proceeds and capital allocation

• Proceeds intended for pipeline development, working capital, and general corporate purposes.

• Management retains broad discretion over allocation, including potential acquisitions, debt repayment, and capital expenditures.